A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

Trial Profile

A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs BMS 986016 (Primary) ; Nivolumab (Primary)
  • Indications Bladder cancer; Gastric cancer; Head and neck cancer; Hepatocellular carcinoma; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 Sep 2017 Planned number of patients changed from 600 to 1000.
    • 30 Jun 2017 Planned primary completion date changed from 6 May 2018 to 6 Jun 2019.
    • 06 Jun 2017 Preliminary efficacy results in patients with melanoma (n=43) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top